GlassScriptPhysician profile
Sevak Valijan
NPI 1346400330
$1,419.51
in general payments reported to CMS, 2019-2025
16 companies · $609 in 2025
The $609 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $73.17 · 2021: $57.76 · 2022: $26.81 · 2023: $161 · 2024: $285 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $281.32 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $199.56 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Dompe US, INC. | $150.26 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $134.49 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $124.08 | 2022-2025 | Cequa |
| Biotissue Holdings INC. | $107.35 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $71.99 | 2025 | |
| Alcon Vision LLC | $54.11 | 2024-2025 | Eysuvis, Tryptyr |
| Oyster Point Pharma, INC. | $54.01 | 2023-2024 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $51.56 | 2024-2025 | Eylea Hd |
| Harrow Eye, LLC | $49.90 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.24 | 2019-2020 | |
| Amgen INC. | $33.43 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $32.77 | 2023 | Rayone Emv, Rayone Spheric, Omidria |
| Novartis Pharmaceuticals Corporation | $19.60 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $17.84 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sevak Valijan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.